瑞慈醫療(01526.HK)料中期淨虧不超1.65億元
格隆匯 8 月 14日丨瑞慈醫療(01526.HK)公告,基於公司目前可得財務資料,預期公司截至2020年6月30日止6個月錄得的公司擁有人應占虧損淨額不超過人民幣1.65億元,而截至2019年6月30日止6個月的公司擁有人應占虧損淨額約人民幣6020萬元。
預期中的公司擁有人應占虧損淨額主要由於截至2020年6月30日止6個月期間的下列因素所致:(i)新冠疫情爆發引致的疫情控制措施對收益產生重大影響,原因為公司於中國各地的體檢中心於疫情期間無法恢復正常營運;及(ii)由於我們的三間專科醫院處於營運初期,導致產生公司擁有人應占虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.